Clinical trials: ACTH
CNS Sarcoidosis
Treatment of CNS Sarcoidosis With H.P. Acthar Gel
The purpose of this study is to see if treatment with H.P. Acthar® Gel will result in the improvement and long-term stabilization of clinical and radiographic abnormalities that occur in patients with CNS sarcoidosis.
- Trial name
- NCT02298491
- Testing
- H.P. Acthar Gel
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Maryland, Baltimore
Proteinuria, Transplant Glomerulopathy
Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.
- Trial name
- NCT02057523
- Testing
- Acthar
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Illinois at Chicago
Uveitis
Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis
Uveitis is an acute or chronic inflammatory condition of unknown etiology. Although uveitis often responds adequately to topical corticosteroids, there are many patients for which this treatment is either inadequate or not…
- Trial name
- NCT02769702
- Testing
- Acthar
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Washington University School of Medicine
Uveitis, Posterior, Uveitis, Intermediate
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
The main reason for this study is to see if Acthar Gel can reduce inflammation in the uvea. Also, safety information when using it for this purpose will be collected.
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- NCT03656692
- Testing
- Acthar Gel
- Where
- 8 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mallinckrodt
Cushing's Disease, Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms…
- Trial name
- NCT01371565
- Testing
- Mifepristone
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Corcept Therapeutics
Kidney Diseases
Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
FSGS is an immunologic disorder wherein circulating immune proteins cause damage to the kidneys and progressive injury and scarring.
- Trial name
- NCT01155141
- Testing
- H.P. Acthar Gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stanford University
Dermatomyositis, Juvenile Dermatomyositis
Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
This study will assess the safety and efficacy of H.P. Acthar gel for treating the cutaneous manifestations in patients with refractory classic dermatomyositis, juvenile dermatomyositis, and amyopathic dermatomyositis.
- Trial name
- NCT02245841
- Testing
- H.P. Acthar Gel
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- The Cleveland Clinic
Sarcoidosis, Pulmonary
Acthar Gel in Participants With Pulmonary Sarcoidosis
The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis. Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a…
- Trial name
- PULSAR (NCT03320070)
- Testing
- Acthar Gel
- Where
- 29 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mallinckrodt
Dry Eye Disease
Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease
Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects with Dry Eye Disease
- Trial name
- NCT03287635
- Testing
- Corticotropin 80Unit/Ml Repository Injection
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Toyos Clinic
Idiopathic Focal Segmental Glomerulosclerosis
Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Focal segmental glomerulosclerosis (FSGS) is a condition that harms the kidney "filters" that remove waste from the blood. Proteins are supposed to stay in the blood. Damaged "filters" let protein get into the kidney.
- Trial name
- PODOCYTE (NCT02633046)
- Testing
- Acthar Gel
- Where
- 47 sites in United States, Argentina and 5 more
- Volunteers
- 63 people
- Sponsor
- Mallinckrodt ARD LLC
Postural Tachycardia Syndrome
Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)
This study is to determine different chemical levels in the blood during a low salt diet. This study will compare normal volunteers to those with Postural Tachycardia Syndrome (POTS)
- Trial name
- NCT01764711
- Testing
- Cosyntropin administration
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Systemic Lupus Erythematosus (SLE)
Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
This Phase 4 study is being performed to examine the effects of Acthar for the indicated use of treatment of SLE. This study will enroll patients with steroid-dependent, persistently active SLE with arthritic and/or cutaneous…
- Trial name
- NCT01753401
- Testing
- Acthar, Steroid Drug
- Where
- 22 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mallinckrodt
Alcohol-Related Disorders, Alcohol Dependence
Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^
Background: Individuals who are dependent on alcohol often have feelings of anxiety, irritability, anger, and depression. These feelings, as well as stress, may contribute to the risk of relapse and continued drinking.
- Conditions
- Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Anxiety Disorder
- Trial name
- NCT01227980
- Testing
- Pexacerfont
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Dependence
CRF1 Antagonist GSK561679 in Alcoholism
Objective: To evaluate GSK561679, an orally available, brain penetrant selective CRH1 antagonist for its ability to reduce alcohol craving in recently detoxified alcohol dependent women in response to stress or alcohol-associated…
- Trial name
- NCT01187511
- Testing
- GSK561679
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Sarcoidosis
Use of CXCL9 as a Biomarker of Acthar Efficacy
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine…
- Trial name
- Acthar (NCT02523092)
- Testing
- Acthar gel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Stress Disorders, Post-Traumatic
Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder
This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of post-traumatic stress disorder (PTSD).
- Trial name
- NCT01018992
- Testing
- GSK561679
- Where
- 4 sites in United States
- Volunteers
- 267 people
- Sponsor
- Emory University
Rheumatoid Arthritis
The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients
The purpose of the study is to evaluate the effect of the utilization of two doses of corticotrophin ( ACTH) as a treatment in patients with early onset rheumatoid arthritis as an alternative to conventional steroid therapy by…
- Trial name
- NCT01948388
- Testing
- corticotrophin 80 units
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gaylis, Norman B., M.D.
Keratitis
Impact of Acthar on Everyday Life of Participants With Severe Keratitis
We will need about 36 participants for this study. Volunteers might be able to participate if: they have bad noninfectious keratitis early treatments failed or were not well tolerated Participants will be in the study for about…
- Trial name
- NCT04169061
- Testing
- Acthar
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mallinckrodt
Membranous Nephropathy
Adrenocorticotropic Hormone in Membranous Nephropathy
The purpose of this study is to evaluate the effect of adrenocorticotropic hormone (ACTH, Acthar) on the loss of proteins in the urine (proteinuria) in patients with membranous nephropathy.
- Trial name
- NCT03025828
- Testing
- ACTHar
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cushings Disease, Cushing Disease
Safety and Efficacy of LCI699 in Cushing's Disease Patients
This exploratory study is a proof of concept study to determine whether LCI699 can safely reduce the level of urinary free cortisol in patients with Cushing's disease.
- Trial name
- NCT01331239
- Testing
- LCI699
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals